nodes	percent_of_prediction	percent_of_DWPC	metapath
Droperidol—Haloperidol—H1F0—hematologic cancer	0.00546	0.74	CrCbGaD
Droperidol—Domperidone—ABCB1—hematologic cancer	0.00074	0.1	CrCbGaD
Droperidol—Rash—Dasatinib—hematologic cancer	0.000665	0.000865	CcSEcCtD
Droperidol—Dermatitis—Dasatinib—hematologic cancer	0.000664	0.000864	CcSEcCtD
Droperidol—Dermatitis—Bexarotene—hematologic cancer	0.000664	0.000864	CcSEcCtD
Droperidol—Rash—Fludarabine—hematologic cancer	0.000663	0.000863	CcSEcCtD
Droperidol—Dermatitis—Fludarabine—hematologic cancer	0.000663	0.000862	CcSEcCtD
Droperidol—Hypertension—Mitoxantrone—hematologic cancer	0.000662	0.000861	CcSEcCtD
Droperidol—Hypertension—Irinotecan—hematologic cancer	0.000662	0.000861	CcSEcCtD
Droperidol—Anaphylactic shock—Ifosfamide—hematologic cancer	0.000659	0.000857	CcSEcCtD
Droperidol—Body temperature increased—Hydroxyurea—hematologic cancer	0.000658	0.000856	CcSEcCtD
Droperidol—Chills—Etoposide—hematologic cancer	0.000657	0.000855	CcSEcCtD
Droperidol—Tachycardia—Carmustine—hematologic cancer	0.000657	0.000855	CcSEcCtD
Droperidol—Shock—Alitretinoin—hematologic cancer	0.000656	0.000854	CcSEcCtD
Droperidol—Hypotension—Thalidomide—hematologic cancer	0.000655	0.000852	CcSEcCtD
Droperidol—Tachycardia—Alitretinoin—hematologic cancer	0.000651	0.000847	CcSEcCtD
Droperidol—Anxiety—Mitoxantrone—hematologic cancer	0.000651	0.000846	CcSEcCtD
Droperidol—Hypertension—Gemcitabine—hematologic cancer	0.000645	0.000839	CcSEcCtD
Droperidol—Dizziness—Nilotinib—hematologic cancer	0.000644	0.000838	CcSEcCtD
Droperidol—Somnolence—Thiotepa—hematologic cancer	0.000644	0.000838	CcSEcCtD
Droperidol—Anaphylactic shock—Vincristine—hematologic cancer	0.000643	0.000836	CcSEcCtD
Droperidol—Dizziness—Imatinib—hematologic cancer	0.000641	0.000834	CcSEcCtD
Droperidol—Hypersensitivity—Melphalan—hematologic cancer	0.00064	0.000832	CcSEcCtD
Droperidol—Dizziness—Cladribine—hematologic cancer	0.00063	0.000819	CcSEcCtD
Droperidol—Hypotension—Carmustine—hematologic cancer	0.000629	0.000818	CcSEcCtD
Droperidol—Anaphylactic shock—Mitoxantrone—hematologic cancer	0.000626	0.000814	CcSEcCtD
Droperidol—Anaphylactic shock—Irinotecan—hematologic cancer	0.000626	0.000814	CcSEcCtD
Droperidol—Hypotension—Alitretinoin—hematologic cancer	0.000623	0.000811	CcSEcCtD
Droperidol—Somnolence—Thalidomide—hematologic cancer	0.000623	0.000811	CcSEcCtD
Droperidol—Hypersensitivity—Lenalidomide—hematologic cancer	0.000622	0.000809	CcSEcCtD
Droperidol—Pimozide—ABCB1—hematologic cancer	0.000618	0.0837	CrCbGaD
Droperidol—Hypotension—Ifosfamide—hematologic cancer	0.000616	0.000801	CcSEcCtD
Droperidol—Shock—Mitoxantrone—hematologic cancer	0.000616	0.000801	CcSEcCtD
Droperidol—Shock—Irinotecan—hematologic cancer	0.000616	0.000801	CcSEcCtD
Droperidol—Rash—Nilotinib—hematologic cancer	0.000614	0.000799	CcSEcCtD
Droperidol—Body temperature increased—Bortezomib—hematologic cancer	0.000614	0.000799	CcSEcCtD
Droperidol—Dermatitis—Nilotinib—hematologic cancer	0.000614	0.000799	CcSEcCtD
Droperidol—Hypersensitivity—Hydroxyurea—hematologic cancer	0.000614	0.000798	CcSEcCtD
Droperidol—Rash—Imatinib—hematologic cancer	0.000611	0.000795	CcSEcCtD
Droperidol—Tachycardia—Mitoxantrone—hematologic cancer	0.000611	0.000795	CcSEcCtD
Droperidol—Dermatitis—Imatinib—hematologic cancer	0.00061	0.000794	CcSEcCtD
Droperidol—Body temperature increased—Bleomycin—hematologic cancer	0.00061	0.000793	CcSEcCtD
Droperidol—Anaphylactic shock—Gemcitabine—hematologic cancer	0.00061	0.000793	CcSEcCtD
Droperidol—Dizziness—Vinblastine—hematologic cancer	0.000604	0.000786	CcSEcCtD
Droperidol—Hypotension—Vincristine—hematologic cancer	0.000601	0.000781	CcSEcCtD
Droperidol—Rash—Cladribine—hematologic cancer	0.0006	0.000781	CcSEcCtD
Droperidol—Hallucination—Betamethasone—hematologic cancer	0.0006	0.000781	CcSEcCtD
Droperidol—Hallucination—Dexamethasone—hematologic cancer	0.0006	0.000781	CcSEcCtD
Droperidol—Body temperature increased—Vinorelbine—hematologic cancer	0.0006	0.00078	CcSEcCtD
Droperidol—Dermatitis—Cladribine—hematologic cancer	0.0006	0.00078	CcSEcCtD
Droperidol—Somnolence—Carmustine—hematologic cancer	0.000598	0.000779	CcSEcCtD
Droperidol—Somnolence—Alitretinoin—hematologic cancer	0.000593	0.000771	CcSEcCtD
Droperidol—Hyperglycaemia—Prednisone—hematologic cancer	0.000592	0.00077	CcSEcCtD
Droperidol—Anxiety—Cisplatin—hematologic cancer	0.000591	0.000768	CcSEcCtD
Droperidol—Somnolence—Ifosfamide—hematologic cancer	0.000586	0.000762	CcSEcCtD
Droperidol—Hypotension—Mitoxantrone—hematologic cancer	0.000585	0.000761	CcSEcCtD
Droperidol—Hypotension—Irinotecan—hematologic cancer	0.000585	0.000761	CcSEcCtD
Droperidol—Depression—Prednisone—hematologic cancer	0.000583	0.000759	CcSEcCtD
Droperidol—Angioedema—Prednisolone—hematologic cancer	0.000575	0.000748	CcSEcCtD
Droperidol—Body temperature increased—Thiotepa—hematologic cancer	0.000573	0.000745	CcSEcCtD
Droperidol—Hypersensitivity—Bortezomib—hematologic cancer	0.000573	0.000745	CcSEcCtD
Droperidol—Hypotension—Gemcitabine—hematologic cancer	0.00057	0.000741	CcSEcCtD
Droperidol—Anaphylactic shock—Cisplatin—hematologic cancer	0.000568	0.000739	CcSEcCtD
Droperidol—Hypersensitivity—Bleomycin—hematologic cancer	0.000568	0.000739	CcSEcCtD
Droperidol—Cardiac arrest—Epirubicin—hematologic cancer	0.000565	0.000734	CcSEcCtD
Droperidol—Haloperidol—ABCB1—hematologic cancer	0.000564	0.0764	CrCbGaD
Droperidol—Syncope—Prednisolone—hematologic cancer	0.000564	0.000734	CcSEcCtD
Droperidol—Loss of consciousness—Etoposide—hematologic cancer	0.000561	0.000729	CcSEcCtD
Droperidol—Hypersensitivity—Vinorelbine—hematologic cancer	0.000559	0.000727	CcSEcCtD
Droperidol—Dizziness—Lenalidomide—hematologic cancer	0.000559	0.000727	CcSEcCtD
Droperidol—Somnolence—Irinotecan—hematologic cancer	0.000556	0.000724	CcSEcCtD
Droperidol—Somnolence—Mitoxantrone—hematologic cancer	0.000556	0.000724	CcSEcCtD
Droperidol—Tachycardia—Cisplatin—hematologic cancer	0.000555	0.000721	CcSEcCtD
Droperidol—Body temperature increased—Thalidomide—hematologic cancer	0.000554	0.000721	CcSEcCtD
Droperidol—Loss of consciousness—Prednisolone—hematologic cancer	0.000553	0.000719	CcSEcCtD
Droperidol—Hypertension—Etoposide—hematologic cancer	0.000551	0.000716	CcSEcCtD
Droperidol—Dizziness—Hydroxyurea—hematologic cancer	0.000551	0.000716	CcSEcCtD
Droperidol—Rash—Melphalan—hematologic cancer	0.000548	0.000712	CcSEcCtD
Droperidol—Dermatitis—Melphalan—hematologic cancer	0.000547	0.000712	CcSEcCtD
Droperidol—Hypertension—Prednisolone—hematologic cancer	0.000543	0.000707	CcSEcCtD
Droperidol—Somnolence—Gemcitabine—hematologic cancer	0.000542	0.000705	CcSEcCtD
Droperidol—Hypersensitivity—Thiotepa—hematologic cancer	0.000534	0.000695	CcSEcCtD
Droperidol—Rash—Lenalidomide—hematologic cancer	0.000533	0.000693	CcSEcCtD
Droperidol—Body temperature increased—Carmustine—hematologic cancer	0.000532	0.000692	CcSEcCtD
Droperidol—Dermatitis—Lenalidomide—hematologic cancer	0.000532	0.000692	CcSEcCtD
Droperidol—Hypotension—Cisplatin—hematologic cancer	0.000531	0.000691	CcSEcCtD
Droperidol—Angioedema—Triamcinolone—hematologic cancer	0.000529	0.000688	CcSEcCtD
Droperidol—Body temperature increased—Alitretinoin—hematologic cancer	0.000527	0.000686	CcSEcCtD
Droperidol—Rash—Hydroxyurea—hematologic cancer	0.000525	0.000683	CcSEcCtD
Droperidol—Dermatitis—Hydroxyurea—hematologic cancer	0.000525	0.000682	CcSEcCtD
Droperidol—Hallucination—Prednisone—hematologic cancer	0.000523	0.00068	CcSEcCtD
Droperidol—Cardiac arrest—Doxorubicin—hematologic cancer	0.000522	0.00068	CcSEcCtD
Droperidol—Body temperature increased—Ifosfamide—hematologic cancer	0.000521	0.000678	CcSEcCtD
Droperidol—Anaphylactic shock—Etoposide—hematologic cancer	0.000521	0.000677	CcSEcCtD
Droperidol—Syncope—Triamcinolone—hematologic cancer	0.000519	0.000675	CcSEcCtD
Droperidol—Hypersensitivity—Thalidomide—hematologic cancer	0.000516	0.000672	CcSEcCtD
Droperidol—Dizziness—Bortezomib—hematologic cancer	0.000514	0.000669	CcSEcCtD
Droperidol—Anaphylactic shock—Prednisolone—hematologic cancer	0.000513	0.000668	CcSEcCtD
Droperidol—Loss of consciousness—Triamcinolone—hematologic cancer	0.000509	0.000661	CcSEcCtD
Droperidol—Tachycardia—Etoposide—hematologic cancer	0.000508	0.000661	CcSEcCtD
Droperidol—Body temperature increased—Vincristine—hematologic cancer	0.000508	0.000661	CcSEcCtD
Droperidol—Shock—Prednisolone—hematologic cancer	0.000505	0.000657	CcSEcCtD
Droperidol—Dizziness—Vinorelbine—hematologic cancer	0.000502	0.000653	CcSEcCtD
Droperidol—Tachycardia—Prednisolone—hematologic cancer	0.000501	0.000652	CcSEcCtD
Droperidol—Hypertension—Triamcinolone—hematologic cancer	0.0005	0.00065	CcSEcCtD
Droperidol—Hypersensitivity—Carmustine—hematologic cancer	0.000496	0.000645	CcSEcCtD
Droperidol—Body temperature increased—Mitoxantrone—hematologic cancer	0.000495	0.000644	CcSEcCtD
Droperidol—Body temperature increased—Irinotecan—hematologic cancer	0.000495	0.000644	CcSEcCtD
Droperidol—Hypersensitivity—Alitretinoin—hematologic cancer	0.000491	0.000639	CcSEcCtD
Droperidol—Rash—Bortezomib—hematologic cancer	0.00049	0.000637	CcSEcCtD
Droperidol—Dermatitis—Bortezomib—hematologic cancer	0.00049	0.000637	CcSEcCtD
Droperidol—Drowsiness—Methotrexate—hematologic cancer	0.000489	0.000636	CcSEcCtD
Droperidol—Depression—Methotrexate—hematologic cancer	0.000488	0.000634	CcSEcCtD
Droperidol—Hypotension—Etoposide—hematologic cancer	0.000486	0.000633	CcSEcCtD
Droperidol—Rash—Bleomycin—hematologic cancer	0.000486	0.000633	CcSEcCtD
Droperidol—Dermatitis—Bleomycin—hematologic cancer	0.000486	0.000632	CcSEcCtD
Droperidol—Hypersensitivity—Ifosfamide—hematologic cancer	0.000486	0.000632	CcSEcCtD
Droperidol—Body temperature increased—Gemcitabine—hematologic cancer	0.000482	0.000627	CcSEcCtD
Droperidol—Angioedema—Betamethasone—hematologic cancer	0.00048	0.000624	CcSEcCtD
Droperidol—Angioedema—Dexamethasone—hematologic cancer	0.00048	0.000624	CcSEcCtD
Droperidol—Dizziness—Thiotepa—hematologic cancer	0.000479	0.000623	CcSEcCtD
Droperidol—Rash—Vinorelbine—hematologic cancer	0.000478	0.000622	CcSEcCtD
Droperidol—Dermatitis—Vinorelbine—hematologic cancer	0.000478	0.000622	CcSEcCtD
Droperidol—Hypersensitivity—Vincristine—hematologic cancer	0.000473	0.000616	CcSEcCtD
Droperidol—Anaphylactic shock—Triamcinolone—hematologic cancer	0.000472	0.000614	CcSEcCtD
Droperidol—Syncope—Betamethasone—hematologic cancer	0.000471	0.000612	CcSEcCtD
Droperidol—Syncope—Dexamethasone—hematologic cancer	0.000471	0.000612	CcSEcCtD
Droperidol—Shock—Triamcinolone—hematologic cancer	0.000465	0.000604	CcSEcCtD
Droperidol—Dizziness—Thalidomide—hematologic cancer	0.000464	0.000603	CcSEcCtD
Droperidol—Hyperglycaemia—Epirubicin—hematologic cancer	0.000463	0.000602	CcSEcCtD
Droperidol—Somnolence—Etoposide—hematologic cancer	0.000463	0.000602	CcSEcCtD
Droperidol—Loss of consciousness—Dexamethasone—hematologic cancer	0.000461	0.0006	CcSEcCtD
Droperidol—Loss of consciousness—Betamethasone—hematologic cancer	0.000461	0.0006	CcSEcCtD
Droperidol—Hypersensitivity—Irinotecan—hematologic cancer	0.000461	0.0006	CcSEcCtD
Droperidol—Hypersensitivity—Mitoxantrone—hematologic cancer	0.000461	0.0006	CcSEcCtD
Droperidol—Tachycardia—Triamcinolone—hematologic cancer	0.000461	0.000599	CcSEcCtD
Droperidol—Drowsiness—Epirubicin—hematologic cancer	0.000458	0.000595	CcSEcCtD
Droperidol—Rash—Thiotepa—hematologic cancer	0.000457	0.000594	CcSEcCtD
Droperidol—Dermatitis—Thiotepa—hematologic cancer	0.000457	0.000594	CcSEcCtD
Droperidol—Hypertension—Betamethasone—hematologic cancer	0.000453	0.00059	CcSEcCtD
Droperidol—Hypertension—Dexamethasone—hematologic cancer	0.000453	0.00059	CcSEcCtD
Droperidol—Body temperature increased—Cisplatin—hematologic cancer	0.000449	0.000584	CcSEcCtD
Droperidol—Anxiety—Dexamethasone—hematologic cancer	0.000445	0.000579	CcSEcCtD
Droperidol—Anxiety—Betamethasone—hematologic cancer	0.000445	0.000579	CcSEcCtD
Droperidol—Dizziness—Carmustine—hematologic cancer	0.000445	0.000579	CcSEcCtD
Droperidol—Rash—Thalidomide—hematologic cancer	0.000442	0.000575	CcSEcCtD
Droperidol—Dermatitis—Thalidomide—hematologic cancer	0.000442	0.000574	CcSEcCtD
Droperidol—Dizziness—Alitretinoin—hematologic cancer	0.000441	0.000574	CcSEcCtD
Droperidol—Dizziness—Ifosfamide—hematologic cancer	0.000436	0.000567	CcSEcCtD
Droperidol—Anaphylactic shock—Dexamethasone—hematologic cancer	0.000428	0.000557	CcSEcCtD
Droperidol—Anaphylactic shock—Betamethasone—hematologic cancer	0.000428	0.000557	CcSEcCtD
Droperidol—Hyperglycaemia—Doxorubicin—hematologic cancer	0.000428	0.000557	CcSEcCtD
Droperidol—Dizziness—Vincristine—hematologic cancer	0.000425	0.000553	CcSEcCtD
Droperidol—Rash—Carmustine—hematologic cancer	0.000424	0.000552	CcSEcCtD
Droperidol—Dermatitis—Carmustine—hematologic cancer	0.000424	0.000552	CcSEcCtD
Droperidol—Drowsiness—Doxorubicin—hematologic cancer	0.000423	0.000551	CcSEcCtD
Droperidol—Shock—Dexamethasone—hematologic cancer	0.000422	0.000548	CcSEcCtD
Droperidol—Shock—Betamethasone—hematologic cancer	0.000422	0.000548	CcSEcCtD
Droperidol—Rash—Alitretinoin—hematologic cancer	0.000421	0.000547	CcSEcCtD
Droperidol—Dermatitis—Alitretinoin—hematologic cancer	0.00042	0.000547	CcSEcCtD
Droperidol—Hypersensitivity—Cisplatin—hematologic cancer	0.000419	0.000545	CcSEcCtD
Droperidol—Tachycardia—Dexamethasone—hematologic cancer	0.000418	0.000544	CcSEcCtD
Droperidol—Tachycardia—Betamethasone—hematologic cancer	0.000418	0.000544	CcSEcCtD
Droperidol—Angioedema—Prednisone—hematologic cancer	0.000418	0.000543	CcSEcCtD
Droperidol—Rash—Ifosfamide—hematologic cancer	0.000416	0.000541	CcSEcCtD
Droperidol—Dermatitis—Ifosfamide—hematologic cancer	0.000415	0.00054	CcSEcCtD
Droperidol—Dizziness—Irinotecan—hematologic cancer	0.000414	0.000538	CcSEcCtD
Droperidol—Body temperature increased—Etoposide—hematologic cancer	0.000412	0.000535	CcSEcCtD
Droperidol—Syncope—Prednisone—hematologic cancer	0.00041	0.000533	CcSEcCtD
Droperidol—Rash—Vincristine—hematologic cancer	0.000405	0.000527	CcSEcCtD
Droperidol—Dermatitis—Vincristine—hematologic cancer	0.000405	0.000527	CcSEcCtD
Droperidol—Loss of consciousness—Prednisone—hematologic cancer	0.000402	0.000523	CcSEcCtD
Droperidol—Hypotension—Dexamethasone—hematologic cancer	0.0004	0.000521	CcSEcCtD
Droperidol—Hypotension—Betamethasone—hematologic cancer	0.0004	0.000521	CcSEcCtD
Droperidol—Hypertension—Prednisone—hematologic cancer	0.000395	0.000513	CcSEcCtD
Droperidol—Rash—Mitoxantrone—hematologic cancer	0.000395	0.000513	CcSEcCtD
Droperidol—Rash—Irinotecan—hematologic cancer	0.000395	0.000513	CcSEcCtD
Droperidol—Dermatitis—Irinotecan—hematologic cancer	0.000394	0.000513	CcSEcCtD
Droperidol—Dermatitis—Mitoxantrone—hematologic cancer	0.000394	0.000513	CcSEcCtD
Droperidol—Chills—Methotrexate—hematologic cancer	0.000394	0.000512	CcSEcCtD
Droperidol—Anxiety—Prednisone—hematologic cancer	0.000388	0.000505	CcSEcCtD
Droperidol—Rash—Gemcitabine—hematologic cancer	0.000384	0.0005	CcSEcCtD
Droperidol—Dermatitis—Gemcitabine—hematologic cancer	0.000384	0.0005	CcSEcCtD
Droperidol—Hypersensitivity—Etoposide—hematologic cancer	0.000384	0.000499	CcSEcCtD
Droperidol—Hypersensitivity—Prednisolone—hematologic cancer	0.000378	0.000492	CcSEcCtD
Droperidol—Body temperature increased—Triamcinolone—hematologic cancer	0.000373	0.000486	CcSEcCtD
Droperidol—Anaphylactic shock—Prednisone—hematologic cancer	0.000373	0.000485	CcSEcCtD
Droperidol—Chills—Epirubicin—hematologic cancer	0.000369	0.000479	CcSEcCtD
Droperidol—Shock—Prednisone—hematologic cancer	0.000367	0.000478	CcSEcCtD
Droperidol—Tachycardia—Prednisone—hematologic cancer	0.000364	0.000474	CcSEcCtD
Droperidol—Rash—Cisplatin—hematologic cancer	0.000358	0.000466	CcSEcCtD
Droperidol—Dermatitis—Cisplatin—hematologic cancer	0.000358	0.000466	CcSEcCtD
Droperidol—Hypersensitivity—Triamcinolone—hematologic cancer	0.000348	0.000453	CcSEcCtD
Droperidol—Dizziness—Etoposide—hematologic cancer	0.000344	0.000448	CcSEcCtD
Droperidol—Chills—Doxorubicin—hematologic cancer	0.000341	0.000444	CcSEcCtD
Droperidol—Dizziness—Prednisolone—hematologic cancer	0.00034	0.000442	CcSEcCtD
Droperidol—Body temperature increased—Dexamethasone—hematologic cancer	0.000339	0.000441	CcSEcCtD
Droperidol—Body temperature increased—Betamethasone—hematologic cancer	0.000339	0.000441	CcSEcCtD
Droperidol—Rash—Etoposide—hematologic cancer	0.000328	0.000427	CcSEcCtD
Droperidol—Dermatitis—Etoposide—hematologic cancer	0.000328	0.000427	CcSEcCtD
Droperidol—Rash—Prednisolone—hematologic cancer	0.000324	0.000421	CcSEcCtD
Droperidol—Dermatitis—Prednisolone—hematologic cancer	0.000323	0.000421	CcSEcCtD
Droperidol—Syncope—Epirubicin—hematologic cancer	0.000321	0.000417	CcSEcCtD
Droperidol—Palpitations—Epirubicin—hematologic cancer	0.000316	0.000411	CcSEcCtD
Droperidol—Loss of consciousness—Epirubicin—hematologic cancer	0.000314	0.000409	CcSEcCtD
Droperidol—Dizziness—Triamcinolone—hematologic cancer	0.000312	0.000406	CcSEcCtD
Droperidol—Anaphylactic shock—Methotrexate—hematologic cancer	0.000312	0.000406	CcSEcCtD
Droperidol—Hypertension—Epirubicin—hematologic cancer	0.000309	0.000402	CcSEcCtD
Droperidol—Anxiety—Epirubicin—hematologic cancer	0.000303	0.000395	CcSEcCtD
Droperidol—Rash—Triamcinolone—hematologic cancer	0.000298	0.000387	CcSEcCtD
Droperidol—Dermatitis—Triamcinolone—hematologic cancer	0.000297	0.000387	CcSEcCtD
Droperidol—Syncope—Doxorubicin—hematologic cancer	0.000297	0.000386	CcSEcCtD
Droperidol—Body temperature increased—Prednisone—hematologic cancer	0.000295	0.000384	CcSEcCtD
Droperidol—Palpitations—Doxorubicin—hematologic cancer	0.000292	0.00038	CcSEcCtD
Droperidol—Anaphylactic shock—Epirubicin—hematologic cancer	0.000292	0.00038	CcSEcCtD
Droperidol—Hypotension—Methotrexate—hematologic cancer	0.000291	0.000379	CcSEcCtD
Droperidol—Loss of consciousness—Doxorubicin—hematologic cancer	0.000291	0.000378	CcSEcCtD
Droperidol—Shock—Epirubicin—hematologic cancer	0.000287	0.000373	CcSEcCtD
Droperidol—Hypertension—Doxorubicin—hematologic cancer	0.000286	0.000372	CcSEcCtD
Droperidol—Tachycardia—Epirubicin—hematologic cancer	0.000285	0.00037	CcSEcCtD
Droperidol—Dizziness—Betamethasone—hematologic cancer	0.000283	0.000369	CcSEcCtD
Droperidol—Dizziness—Dexamethasone—hematologic cancer	0.000283	0.000369	CcSEcCtD
Droperidol—Anxiety—Doxorubicin—hematologic cancer	0.000281	0.000365	CcSEcCtD
Droperidol—Somnolence—Methotrexate—hematologic cancer	0.000277	0.000361	CcSEcCtD
Droperidol—Hypersensitivity—Prednisone—hematologic cancer	0.000275	0.000358	CcSEcCtD
Droperidol—Hypotension—Epirubicin—hematologic cancer	0.000273	0.000355	CcSEcCtD
Droperidol—Rash—Betamethasone—hematologic cancer	0.00027	0.000351	CcSEcCtD
Droperidol—Rash—Dexamethasone—hematologic cancer	0.00027	0.000351	CcSEcCtD
Droperidol—Anaphylactic shock—Doxorubicin—hematologic cancer	0.00027	0.000351	CcSEcCtD
Droperidol—Dermatitis—Betamethasone—hematologic cancer	0.00027	0.000351	CcSEcCtD
Droperidol—Dermatitis—Dexamethasone—hematologic cancer	0.00027	0.000351	CcSEcCtD
Droperidol—Shock—Doxorubicin—hematologic cancer	0.000266	0.000346	CcSEcCtD
Droperidol—Tachycardia—Doxorubicin—hematologic cancer	0.000264	0.000343	CcSEcCtD
Droperidol—Somnolence—Epirubicin—hematologic cancer	0.000259	0.000337	CcSEcCtD
Droperidol—Hypotension—Doxorubicin—hematologic cancer	0.000252	0.000328	CcSEcCtD
Droperidol—Dizziness—Prednisone—hematologic cancer	0.000247	0.000321	CcSEcCtD
Droperidol—Body temperature increased—Methotrexate—hematologic cancer	0.000247	0.000321	CcSEcCtD
Droperidol—Somnolence—Doxorubicin—hematologic cancer	0.00024	0.000312	CcSEcCtD
Droperidol—Rash—Prednisone—hematologic cancer	0.000235	0.000306	CcSEcCtD
Droperidol—Dermatitis—Prednisone—hematologic cancer	0.000235	0.000306	CcSEcCtD
Droperidol—Body temperature increased—Epirubicin—hematologic cancer	0.000231	0.0003	CcSEcCtD
Droperidol—Hypersensitivity—Methotrexate—hematologic cancer	0.00023	0.000299	CcSEcCtD
Droperidol—Hypersensitivity—Epirubicin—hematologic cancer	0.000215	0.00028	CcSEcCtD
Droperidol—Body temperature increased—Doxorubicin—hematologic cancer	0.000213	0.000278	CcSEcCtD
Droperidol—Dizziness—Methotrexate—hematologic cancer	0.000206	0.000268	CcSEcCtD
Droperidol—Hypersensitivity—Doxorubicin—hematologic cancer	0.000199	0.000259	CcSEcCtD
Droperidol—Rash—Methotrexate—hematologic cancer	0.000197	0.000256	CcSEcCtD
Droperidol—Dermatitis—Methotrexate—hematologic cancer	0.000196	0.000256	CcSEcCtD
Droperidol—Dizziness—Epirubicin—hematologic cancer	0.000193	0.000251	CcSEcCtD
Droperidol—Rash—Epirubicin—hematologic cancer	0.000184	0.000239	CcSEcCtD
Droperidol—Dermatitis—Epirubicin—hematologic cancer	0.000184	0.000239	CcSEcCtD
Droperidol—Dizziness—Doxorubicin—hematologic cancer	0.000179	0.000232	CcSEcCtD
Droperidol—Rash—Doxorubicin—hematologic cancer	0.00017	0.000221	CcSEcCtD
Droperidol—Dermatitis—Doxorubicin—hematologic cancer	0.00017	0.000221	CcSEcCtD
Droperidol—DRD2—GPCR downstream signaling—JAK2—hematologic cancer	3.71e-05	0.000166	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—MAP2K1—hematologic cancer	3.7e-05	0.000165	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—PIK3R1—hematologic cancer	3.68e-05	0.000164	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—GRB2—hematologic cancer	3.68e-05	0.000164	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—PIK3CD—hematologic cancer	3.68e-05	0.000164	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PDGFA—hematologic cancer	3.67e-05	0.000164	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—JAK2—hematologic cancer	3.65e-05	0.000163	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—MAP2K1—hematologic cancer	3.64e-05	0.000163	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—GRB2—hematologic cancer	3.62e-05	0.000162	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—KITLG—hematologic cancer	3.62e-05	0.000162	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—PIK3CD—hematologic cancer	3.62e-05	0.000162	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PDGFA—hematologic cancer	3.61e-05	0.000161	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—JAK2—hematologic cancer	3.58e-05	0.00016	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—MAP2K1—hematologic cancer	3.56e-05	0.000159	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—KITLG—hematologic cancer	3.56e-05	0.000159	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—GRB2—hematologic cancer	3.55e-05	0.000158	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—PIK3CD—hematologic cancer	3.54e-05	0.000158	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PDGFA—hematologic cancer	3.54e-05	0.000158	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—STAT5A—hematologic cancer	3.54e-05	0.000158	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—PIK3CB—hematologic cancer	3.53e-05	0.000158	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CDKN2B—hematologic cancer	3.51e-05	0.000157	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—KITLG—hematologic cancer	3.49e-05	0.000156	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—STAT5A—hematologic cancer	3.48e-05	0.000155	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—PIK3CB—hematologic cancer	3.47e-05	0.000155	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—PIK3R1—hematologic cancer	3.47e-05	0.000155	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CDKN2B—hematologic cancer	3.45e-05	0.000154	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—PIK3R1—hematologic cancer	3.42e-05	0.000153	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—STAT5A—hematologic cancer	3.41e-05	0.000152	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—PIK3CB—hematologic cancer	3.4e-05	0.000152	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CD86—hematologic cancer	3.39e-05	0.000152	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CDKN2B—hematologic cancer	3.38e-05	0.000151	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—JAK2—hematologic cancer	3.37e-05	0.000151	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—HES1—hematologic cancer	3.35e-05	0.000149	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—PIK3R1—hematologic cancer	3.34e-05	0.000149	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CD86—hematologic cancer	3.34e-05	0.000149	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—NCOR1—hematologic cancer	3.33e-05	0.000149	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—JAK2—hematologic cancer	3.32e-05	0.000148	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—HES1—hematologic cancer	3.29e-05	0.000147	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—FGF1—hematologic cancer	3.29e-05	0.000147	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CSF2—hematologic cancer	3.29e-05	0.000147	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—NCOR1—hematologic cancer	3.27e-05	0.000146	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CD86—hematologic cancer	3.27e-05	0.000146	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—JAK2—hematologic cancer	3.25e-05	0.000145	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—FOXO1—hematologic cancer	3.24e-05	0.000145	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—IL2—hematologic cancer	3.24e-05	0.000145	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—FGF1—hematologic cancer	3.24e-05	0.000145	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CSF2—hematologic cancer	3.24e-05	0.000145	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PDGFRB—hematologic cancer	3.24e-05	0.000145	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—HES1—hematologic cancer	3.22e-05	0.000144	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—NCOR1—hematologic cancer	3.2e-05	0.000143	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—PIK3CB—hematologic cancer	3.2e-05	0.000143	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—FOXO1—hematologic cancer	3.19e-05	0.000142	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—IL2—hematologic cancer	3.19e-05	0.000142	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PDGFRA—hematologic cancer	3.19e-05	0.000142	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PDGFRB—hematologic cancer	3.18e-05	0.000142	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—JAK1—hematologic cancer	3.17e-05	0.000142	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PRKCG—hematologic cancer	3.17e-05	0.000142	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CSF2—hematologic cancer	3.17e-05	0.000142	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—FGF1—hematologic cancer	3.17e-05	0.000142	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—PIK3CB—hematologic cancer	3.15e-05	0.000141	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PDGFRA—hematologic cancer	3.13e-05	0.00014	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—JAK1—hematologic cancer	3.12e-05	0.00014	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PRKCG—hematologic cancer	3.12e-05	0.00014	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—FOXO1—hematologic cancer	3.12e-05	0.000139	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—IL2—hematologic cancer	3.12e-05	0.000139	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PDGFRB—hematologic cancer	3.12e-05	0.000139	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—PIK3CB—hematologic cancer	3.09e-05	0.000138	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PDGFRA—hematologic cancer	3.07e-05	0.000137	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PRKCG—hematologic cancer	3.06e-05	0.000137	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—JAK1—hematologic cancer	3.06e-05	0.000137	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—IL2RA—hematologic cancer	2.96e-05	0.000132	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—IL2—hematologic cancer	2.94e-05	0.000131	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—TERT—hematologic cancer	2.93e-05	0.000131	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—IL2RA—hematologic cancer	2.92e-05	0.00013	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—IL2—hematologic cancer	2.89e-05	0.000129	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—TERT—hematologic cancer	2.88e-05	0.000129	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PDGFB—hematologic cancer	2.86e-05	0.000128	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—IL2RA—hematologic cancer	2.86e-05	0.000128	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—IL2—hematologic cancer	2.83e-05	0.000127	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—TERT—hematologic cancer	2.82e-05	0.000126	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PDGFB—hematologic cancer	2.82e-05	0.000126	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—TSC2—hematologic cancer	2.8e-05	0.000125	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PDGFB—hematologic cancer	2.76e-05	0.000123	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—TSC2—hematologic cancer	2.75e-05	0.000123	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—TSC2—hematologic cancer	2.69e-05	0.00012	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—FGFR3—hematologic cancer	2.69e-05	0.00012	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MAPK14—hematologic cancer	2.66e-05	0.000119	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—FGFR3—hematologic cancer	2.65e-05	0.000118	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MAPK14—hematologic cancer	2.62e-05	0.000117	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—ESR1—hematologic cancer	2.61e-05	0.000117	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—FGFR3—hematologic cancer	2.59e-05	0.000116	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—FN1—hematologic cancer	2.58e-05	0.000115	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—ESR1—hematologic cancer	2.57e-05	0.000115	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MAPK14—hematologic cancer	2.57e-05	0.000115	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—NFKBIA—hematologic cancer	2.55e-05	0.000114	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—BAD—hematologic cancer	2.55e-05	0.000114	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—FN1—hematologic cancer	2.54e-05	0.000113	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—NOTCH1—hematologic cancer	2.53e-05	0.000113	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—ESR1—hematologic cancer	2.52e-05	0.000112	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—BAD—hematologic cancer	2.51e-05	0.000112	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—NFKBIA—hematologic cancer	2.51e-05	0.000112	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—FN1—hematologic cancer	2.49e-05	0.000111	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—NOTCH1—hematologic cancer	2.49e-05	0.000111	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CD80—hematologic cancer	2.47e-05	0.000111	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—KIT—hematologic cancer	2.47e-05	0.00011	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PIK3CG—hematologic cancer	2.47e-05	0.00011	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—NRAS—hematologic cancer	2.47e-05	0.00011	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—BAD—hematologic cancer	2.46e-05	0.00011	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—NFKBIA—hematologic cancer	2.46e-05	0.00011	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CD80—hematologic cancer	2.43e-05	0.000109	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—NOTCH1—hematologic cancer	2.43e-05	0.000109	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PIK3CG—hematologic cancer	2.43e-05	0.000109	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—KIT—hematologic cancer	2.43e-05	0.000109	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—NRAS—hematologic cancer	2.43e-05	0.000109	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PTPN11—hematologic cancer	2.43e-05	0.000108	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PTPN11—hematologic cancer	2.39e-05	0.000107	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CD80—hematologic cancer	2.38e-05	0.000106	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PIK3CG—hematologic cancer	2.38e-05	0.000106	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—KIT—hematologic cancer	2.38e-05	0.000106	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—NRAS—hematologic cancer	2.38e-05	0.000106	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—MAPK3—hematologic cancer	2.37e-05	0.000106	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CREB1—hematologic cancer	2.35e-05	0.000105	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PTPN11—hematologic cancer	2.34e-05	0.000104	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—MAPK3—hematologic cancer	2.33e-05	0.000104	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—BRAF—hematologic cancer	2.32e-05	0.000104	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CREB1—hematologic cancer	2.31e-05	0.000103	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CCL2—hematologic cancer	2.3e-05	0.000103	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—IL6R—hematologic cancer	2.29e-05	0.000102	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CREBBP—hematologic cancer	2.29e-05	0.000102	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—BRAF—hematologic cancer	2.28e-05	0.000102	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—MAPK3—hematologic cancer	2.28e-05	0.000102	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CREB1—hematologic cancer	2.27e-05	0.000101	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CCL2—hematologic cancer	2.26e-05	0.000101	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—IL6R—hematologic cancer	2.26e-05	0.000101	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CREBBP—hematologic cancer	2.25e-05	0.000101	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—BRAF—hematologic cancer	2.24e-05	9.99e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CCL2—hematologic cancer	2.22e-05	9.9e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—IL6R—hematologic cancer	2.21e-05	9.87e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CREBBP—hematologic cancer	2.21e-05	9.85e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MAP2K1—hematologic cancer	2.19e-05	9.76e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PIK3CD—hematologic cancer	2.17e-05	9.7e-05	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—PIK3CA—hematologic cancer	2.15e-05	9.61e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MAP2K1—hematologic cancer	2.15e-05	9.61e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PIK3CD—hematologic cancer	2.14e-05	9.54e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—KRAS—hematologic cancer	2.13e-05	9.5e-05	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—PIK3CA—hematologic cancer	2.12e-05	9.45e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MAP2K1—hematologic cancer	2.11e-05	9.41e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PIK3CD—hematologic cancer	2.09e-05	9.34e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—KRAS—hematologic cancer	2.09e-05	9.34e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—FGF2—hematologic cancer	2.08e-05	9.29e-05	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—PIK3CA—hematologic cancer	2.07e-05	9.26e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PIK3R1—hematologic cancer	2.05e-05	9.16e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—KRAS—hematologic cancer	2.05e-05	9.15e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—FGF2—hematologic cancer	2.05e-05	9.14e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PIK3R1—hematologic cancer	2.02e-05	9.01e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—FGF2—hematologic cancer	2e-05	8.95e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—JAK2—hematologic cancer	1.99e-05	8.9e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PIK3R1—hematologic cancer	1.98e-05	8.82e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—JAK2—hematologic cancer	1.96e-05	8.76e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—PIK3CA—hematologic cancer	1.95e-05	8.72e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MDM2—hematologic cancer	1.95e-05	8.69e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—PIK3CA—hematologic cancer	1.92e-05	8.58e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—JAK2—hematologic cancer	1.92e-05	8.58e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MDM2—hematologic cancer	1.91e-05	8.55e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MTOR—hematologic cancer	1.89e-05	8.45e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PIK3CB—hematologic cancer	1.89e-05	8.45e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—PIK3CA—hematologic cancer	1.88e-05	8.4e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MDM2—hematologic cancer	1.87e-05	8.37e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MTOR—hematologic cancer	1.86e-05	8.32e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PIK3CB—hematologic cancer	1.86e-05	8.32e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MTOR—hematologic cancer	1.82e-05	8.14e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PIK3CB—hematologic cancer	1.82e-05	8.14e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—HRAS—hematologic cancer	1.81e-05	8.07e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—HRAS—hematologic cancer	1.78e-05	7.94e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CDKN1B—hematologic cancer	1.78e-05	7.93e-05	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—AKT1—hematologic cancer	1.76e-05	7.85e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	1.75e-05	7.81e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	1.74e-05	7.78e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CASP3—hematologic cancer	1.74e-05	7.78e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—IL2—hematologic cancer	1.74e-05	7.76e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—IL6—hematologic cancer	1.73e-05	7.72e-05	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	1.73e-05	7.72e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CASP3—hematologic cancer	1.71e-05	7.65e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	1.71e-05	7.64e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—IL2—hematologic cancer	1.71e-05	7.64e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—IL6—hematologic cancer	1.7e-05	7.6e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CCND1—hematologic cancer	1.69e-05	7.57e-05	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	1.69e-05	7.56e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—JUN—hematologic cancer	1.69e-05	7.55e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	1.68e-05	7.49e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—IL2—hematologic cancer	1.67e-05	7.48e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CCND1—hematologic cancer	1.67e-05	7.45e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	1.67e-05	7.44e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—JUN—hematologic cancer	1.66e-05	7.43e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	1.64e-05	7.32e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PTEN—hematologic cancer	1.64e-05	7.3e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	1.63e-05	7.29e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—JUN—hematologic cancer	1.63e-05	7.28e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	1.61e-05	7.2e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PTEN—hematologic cancer	1.61e-05	7.19e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MAPK8—hematologic cancer	1.6e-05	7.15e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—AKT1—hematologic cancer	1.6e-05	7.13e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	1.58e-05	7.05e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	1.58e-05	7.04e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	1.57e-05	7.03e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	1.57e-05	7.01e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—EP300—hematologic cancer	1.56e-05	6.97e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	1.54e-05	6.88e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	1.54e-05	6.87e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—EP300—hematologic cancer	1.53e-05	6.85e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—SRC—hematologic cancer	1.52e-05	6.77e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—EP300—hematologic cancer	1.5e-05	6.71e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—SRC—hematologic cancer	1.49e-05	6.67e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—VEGFA—hematologic cancer	1.48e-05	6.6e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—STAT3—hematologic cancer	1.46e-05	6.53e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—SRC—hematologic cancer	1.46e-05	6.53e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—NRAS—hematologic cancer	1.46e-05	6.52e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	1.45e-05	6.49e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—STAT3—hematologic cancer	1.44e-05	6.43e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—NRAS—hematologic cancer	1.44e-05	6.41e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	1.42e-05	6.36e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	1.41e-05	6.29e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	1.41e-05	6.28e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MAPK3—hematologic cancer	1.4e-05	6.24e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	1.37e-05	6.14e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MYC—hematologic cancer	1.36e-05	6.07e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—TGFB1—hematologic cancer	1.36e-05	6.06e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	1.35e-05	6.01e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MYC—hematologic cancer	1.34e-05	5.97e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	1.33e-05	5.96e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MYC—hematologic cancer	1.31e-05	5.85e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	1.31e-05	5.83e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—KRAS—hematologic cancer	1.26e-05	5.61e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—KRAS—hematologic cancer	1.24e-05	5.52e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	1.21e-05	5.4e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	1.15e-05	5.15e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	1.14e-05	5.07e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—TP53—hematologic cancer	1.12e-05	4.99e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	1.11e-05	4.96e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—TP53—hematologic cancer	1.1e-05	4.91e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—TP53—hematologic cancer	1.08e-05	4.8e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—HRAS—hematologic cancer	1.07e-05	4.77e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—HRAS—hematologic cancer	1.05e-05	4.69e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	1.03e-05	4.59e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—IL6—hematologic cancer	1.02e-05	4.56e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—IL6—hematologic cancer	1.01e-05	4.49e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—IL6—hematologic cancer	9.84e-06	4.4e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—AKT1—hematologic cancer	9.42e-06	4.21e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—AKT1—hematologic cancer	9.27e-06	4.14e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	9.08e-06	4.06e-05	CbGpPWpGaD
